253
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Tear Protein Markers for Diabetic Retinopathy and Diabetic Macular Edema – Towards an Early Diagnosis and Better Prognosis

, , , , ORCID Icon, , , ORCID Icon & show all
Received 06 Feb 2024, Accepted 01 Apr 2024, Published online: 20 Apr 2024

REFERENCES

  • Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in India: a review of IDF diabetes atlas 10th Edition. Curr Diabetes Rev. 2023;20(1): doi:10.2174/1573399819666230413094200.
  • Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019;7(2):140–149. doi:10.1016/S2213-8587(18)30128-1.
  • Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–1682. doi:10.1016/S0161-6420(03)00475-5.
  • Cheung N, Cheung CMG, Talks SJ, et al. Management of diabetic macular oedema: new insights and global implications of DRCR protocol V. Eye (Lond). 2020;34(6):999–1002. doi:10.1038/s41433-019-0738-y.
  • Dai L, Wu L, Li H, et al. A deep learning system for detecting diabetic retinopathy across the disease spectrum. Nat Commun. 2021;12(1):3242. doi:10.1038/s41467-021-23458-5.
  • Ghosh S. Change in tear protein profile in diabetic retinopathy with duration of diabetes. Diab Metab Syndr. 2014;8(4):233–235. doi:10.1016/j.dsx.2014.09.019.
  • Zhan X. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine. Epma J. 2021;12(4):449–475. doi:10.1007/s13167-021-00265-y.
  • Kropp M. Short communication: unique metabolic signature of proliferative retinopathy in the tear fluid of diabetic patients with comorbidities - preliminary data for PPPM validation. Epma J. 2023;14(1):43–51. doi:10.1007/s13167-023-00318-4.
  • Wu Y. Advances in dry eye disease examination techniques. Front Med. 2021;8:826530. doi:10.3389/fmed.2021.826530.
  • Pieczynski J, Szulc U, Harazna J. Tear fluid collection methods: review of current techniques. Eur J Ophthalmol. 2021;31(5):2245–2251. doi:10.1177/1120672121998922.
  • Lopez-Cisternas J, Castillo-Díaz J, Traipe-Castro L, et al. Use of polyurethane minisponges to collect human tear fluid. Cornea. 2006;25(3):312–318. doi:10.1097/01.ico.0000183531.25201.0d.
  • Esmaeelpour M, Cai J, Watts P, et al. Tear sample collection using cellulose acetate absorbent filters. Ophthalmic Physiol Opt. 2008;28(6):577–583. doi:10.1111/j.1475-1313.2008.00603.x.
  • Zhou L, Beuerman RW. Tear analysis in ocular surface diseases. Prog Retin Eye Res. 2012;31(6):527–550. doi:10.1016/j.preteyeres.2012.06.002.
  • Raju KS. Utility of noninvasive biomatrices in pharmacokinetic studies. Biomed Chromatogr. 2013;27(10):1354–1366. doi:10.1002/bmc.2996.
  • Patnaik S, Rai M, Jalali S, et al. An interplay of microglia and matrix metalloproteinase MMP9 under hypoxic stress regulates the opticin expression in retina. Sci Rep. 2021;11(1):7444. doi:10.1038/s41598-021-86302-2.
  • Kastelan S. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Med (Zagreb). 2020;30(3):030502. doi:10.11613/BM.2020.030502.
  • Ouchi M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res. 2005;81(2):176–182. doi:10.1016/j.exer.2005.01.020.
  • Shitama T. Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl. 2008;2(9):1265–1280. doi:10.1002/prca.200800017.
  • Hernandez C. Identification of new pathogenic candidates for diabetic macular edema using fluorescence-based difference gel electrophoresis analysis. Diabetes Metab Res Rev. 2013;29(6):499–506. doi:10.1002/dmrr.2419.
  • Kita T, Clermont AC, Murugesan N, et al. Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes. 2015;64(10):3588–3599. doi:10.2337/db15-0317.
  • Srividya G, Jain M, Mahalakshmi K, et al. A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema. Eye (Lond). 2018;32(4):820–829. doi:10.1038/eye.2017.285.
  • Yenihayat F, Özkan B, Kasap M, et al. Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol. 2019;39(4):821–828. doi:10.1007/s10792-018-0874-6.
  • Burgos-Blasco B. Tear and aqueous humour cytokine profile in primary open-angle glaucoma. Acta Ophthalmol. 2020;98(6):e768–e772. doi:10.1111/aos.14374.
  • Lopez-Miguel A. Clinical and molecular inflammatory response in Sjogren syndrome-associated dry eye patients under desiccating stress. Am J Ophthalmol. 2016;161:133–41 e1–2. doi:10.1016/j.ajo.2015.09.039.
  • Lambiase A. Alterations of tear neuromediators in dry eye disease. Arch Ophthalmol. 2011;129(8):981–986. doi:10.1001/archophthalmol.2011.200.
  • Lam SM. Lipidomic analysis of human tear fluid reveals structure-specific lipid alterations in dry eye syndrome. J Lipid Res. 2014;55(2):299–306. doi:10.1194/jlr.P041780.
  • Lam SM, Tong L, Yong SS, et al. Meibum lipid composition in Asians with dry eye disease. PLOS ONE. 2011;6(10):e24339. doi:10.1371/journal.pone.0024339.
  • Galbis-Estrada C. Differential effects of dry eye disorders on metabolomic profile by 1H nuclear magnetic resonance spectroscopy. Biomed Res Int. 2014;2014:542549. doi:10.1155/2014/542549.
  • Pannebaker C, Chandler HL, Nichols JJ. Tear proteomics in keratoconus. Mol Vis. 2010;16:1949–1957.
  • Lema I, Duran JA. Inflammatory molecules in the tears of patients with keratoconus. Ophthalmology. 2005;112(4):654–659. doi:10.1016/j.ophtha.2004.11.050.
  • Di Girolamo N, Chui J, Coroneo MT, et al. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004;23(2):195–228. doi:10.1016/j.preteyeres.2004.02.002.
  • Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol. 2007;91(1):29–32. doi:10.1136/bjo.2006.101485.
  • Csosz É, Deák E, Tóth N, et al. Comparative analysis of cytokine profiles of glaucomatous tears and aqueous humour reveals potential biomarkers for trabeculectomy complications. FEBS Open Bio. 2019;9(5):1020–1028. doi:10.1002/2211-5463.12637.
  • Winiarczyk M, Kaarniranta K, Winiarczyk S, et al. Tear film proteome in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2018;256(6):1127–1139. doi:10.1007/s00417-018-3984-y.
  • Rathi S, Jalali S, Patnaik S, et al. Abnormal complement activation and inflammation in the pathogenesis of retinopathy of prematurity. Front Immunol. 2017;8:1868. doi:10.3389/fimmu.2017.01868.
  • Magnani JE. Quantitative analysis of tear angiogenic factors in retinopathy of prematurity: a pilot biomarker study. J AAPOS. 2023;27(1):e14 1–e14 6. doi:10.1016/j.jaapos.2022.10.007.
  • Ecaterina P. Glutathione-related antioxidant defense system in patients with hypertensive retinopathy. Rom J Ophthalmol. 2021;65(1):46–53. doi:10.22336/rjo.2021.9.
  • Versura P, Bavelloni A, Grillini M, et al. Diagnostic performance of a tear protein panel in early dry eye. Mol Vis. 2013;19:1247–1257.
  • Amorim M Putative Biomarkers in Tears for diabetic retinopathy diagnosis. Front Med (Lausanne). 2022;9:873483. doi:10.3389/fmed.2022.873483.
  • Kim HJ. Comparison of tear proteins between healthy and early diabetic retinopathy patients. Clin Biochem. 2012;45(1–2):60–67. doi:10.1016/j.clinbiochem.2011.10.006.
  • Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta. 2000;1482(1–2):298–307. doi:10.1016/S0167-4838(00)00163-1.
  • Al-Taee IK, Al-Safar JJ, Al-Falahi YS, et al. The clinical significance of beta2-microglobulin in end-stage renal disease. Saudi J Kidney Dis Transpl. 2003;14(4):492–496.
  • Csosz E. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics. 2012;75(7):2196–2204. doi:10.1016/j.jprot.2012.01.019.
  • Amil-Bangsa NH. Total protein concentration and tumor necrosis factor alpha in tears of nonproliferative diabetic retinopathy. Optom Vis Sci. 2019;96(12):934–939. doi:10.1097/OPX.0000000000001456.
  • Sorkhabi R. Assessment of tear inflammatory cytokines concentration in patients with diabetes with varying severity of involvement. Exp Eye Res. 2022;224:109233. doi:10.1016/j.exer.2022.109233.
  • Liu J, Shi B, He S, et al. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Mol Vis. 2010;16:2931–2938.
  • Ang WJ, Zunaina E, Norfadzillah AJ, et al. Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients. PLOS ONE. 2019;14(8):e0221481. doi:10.1371/journal.pone.0221481.
  • Hashemi H, Ahmadi H, Rostami Z, et al. The role of endothelial growth factor and tear levels in diabetic retinopathy in type 2 diabetes. Int Ophthalmol. 2024;44(1):143. doi:10.1007/s10792-024-03064-2.
  • Jasmiad NB, Abd Ghani RB, Agarwal R. Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy. BMC Ophthalmol. 2022;22(1):357. doi:10.1186/s12886-022-02550-4.
  • Chan HW. A pilot study on MicroRNA profile in tear fluid to predict response to anti-VEGF treatments for diabetic macular edema. JCM. 2020;9(9):2920. doi:10.3390/jcm9092920.
  • Kim M, Zhang X. The profiling and role of miRnas in diabetes mellitus. J Diabetes Clin Res. 2019;1:5–23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.